CompletedPhase 1/2

Healthy Body, Healthy Bones After Bariatric Surgery Trial

United States10 participantsStarted 2020-09-01

Plain-language summary

One in three adults in the United States suffers from obesity. Bariatric surgery is an increasingly utilized and effective treatment for obesity and obesity-related comorbidities, however, the massive weight loss associated with bariatric surgery adversely affects bone leads to an increased risk of fracture. Bisphosphonate medications, such as zoledronic acid, are used to treat bone loss in patients with osteoporosis, and this study investigates whether this medication can prevent bone loss associated with surgical weight loss procedures.

Who can participate

Age range19 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Subjects planning a sleeve gastrectomy procedure at the University of Nebraska Medical Center (UNMC) Bariatric Center * Agreement to all study procedures and assessments * Women must be postmenopausal (FSH blood level \> 30 mIU/m), or incapable of child-bearing Exclusion Criteria: * Prior bariatric surgery * \< 19 years of age * Weight ≥ 350lbs * Liver or renal disease * Hypercalcemia, hypocalcemia, or hypomagnesemia * Serum 25-OH vitamin D \< 20 ng/mL * History of bone-modifying disorders * Use of bone-active medications * Known sensitivity to bisphosphonates * Extensive dental work involving extraction or dental implant within the past 2 months or planned in the upcoming 6 months * Current diagnosis of type 1 diabetes * Current malignancy * Autoimmune disease impacting bone (ex: Rheumatoid Arthritis)

What they're measuring

Change in Hip Bone Mineral Density (BMD)

Timeframe: baseline and 10 months post-surgery

Trial details

NCT IDNCT04279392

SponsorUniversity of Nebraska

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2022-12-30

Results submitted2024-05-07